NCT07509177 An Examination of Whether Infrared Light Therapy Can Reduce Stress in People With Epilepsy
| NCT ID | NCT07509177 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Cynthia Kerson |
| Condition | Epilepsy |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2025-08-11 |
| Primary Completion | 2026-08-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 80 participants in total. It began in 2025-08-11 with a primary completion date of 2026-08-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Do you have Epilepsy? Would you like to participate in a study using PhotoBioModulation (PBM)? PBM is being researched for potential benefits in resolving many stress-related brain disorders. It is a non-invasive technique that delivers light energy to cells and tissues that can promote brain stabilization and self-regulation, cell repair, reduce oxidative stress, and enhance cellular function. We ask you to participate for about 3-4 months and come to our facility for 30 minute sessions 3x a week for 15 weeks. You will receive extensive metabolic testing and an Õura ring for your participation.
Eligibility Criteria
Inclusion Criteria: * • \>18 YO * Epilepsy - medical diagnosis with at least one seizure within the past 6 months: diagnosis to be obtained from medical records from the treating physician by signature of HIPAA-compliant medical release form * Agreement to maintain or reduce medication regimen (based upon prescribers' advice) * Available for intake, baseline, post-treatment, 6-month follow-up assessments, and 45 sessions of PBM * Willingness to wear an Õura ring at all times (except for charging) for the duration of the study. Exclusion: * \< 17 YO * Substance use * Personality disorders * Heavy metal toxicity * Mold toxicity * Metabolic measures thresholded based on participant type * Increase in current medication (dosage and/or type) * No new medications prescribed (reduction as prescribed by prescribing physician OK) * Current brain bleed * Acute TBI within the last 12 months * History of neuromodulation, including ECT * Brain implants/pumps/shunts * History of brain surgery * Hormone replacement therapy for menopause or gender transition * Untreated sleep disorders Exclusion Criteria: \-
Contact & Investigator
Cynthia Kerson, PhD
PRINCIPAL INVESTIGATOR
Saybrook University
Frequently Asked Questions
Who can join the NCT07509177 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07509177 currently recruiting?
Yes, NCT07509177 is actively recruiting participants. Contact the research team at ckerson@saybrook.edu for enrollment information.
Where is the NCT07509177 trial being conducted?
This trial is being conducted at North Miami, United States, Cincinnati, United States, Warren, United States, Houston, United States.
Who is sponsoring the NCT07509177 clinical trial?
NCT07509177 is sponsored by Cynthia Kerson. The principal investigator is Cynthia Kerson, PhD at Saybrook University. The trial plans to enroll 80 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.